Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis

Autoimmunity Reviews

Volumn 12, Issue 9, 2013, Pages 885-893

  Berrih Aknin, Sonia ^a   Ragheb, Samia ^b   Le Panse, Rozen ^a   Lisak, Robert P ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b OAKLAND UNIVERSITY WILLIAM BEAUMONT SCHOOL OF MEDICINE   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti acetylcholine receptor antibodies; Anti B cell therapies; B cells; BAFF; Germinal centers; Myasthenia gravis

Indexed keywords

ATACICEPT; B CELL ACTIVATING FACTOR; BELIMUMAB; CXCL13 CHEMOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN; INTERLEUKIN 6; RITUXIMAB; STROMAL CELL DERIVED FACTOR 1; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ADOPTIVE TRANSFER; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CORTICOSTEROID THERAPY; DISEASE SEVERITY; GERMINAL CENTER; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INNATE IMMUNITY; MEMORY CELL; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; NONHODGKIN LYMPHOMA; NONHUMAN; POLYCLONAL ACTIVATION; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; GERMINAL CENTER; HUMANS; MYASTHENIA GRAVIS; THYMUS GLAND;

EID: 84879167016     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.03.011     Document Type: Review

References (190)

1. Evoli A. Clinical aspects of neuromuscular transmission disorders. Acta Neurol Scand Suppl 2006, 183:8-11.
2. Zhang B., Tzartos J.S., Belimezi M., Ragheb S., Bealmear B., Lewis R.A., et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012, 69:445-451.
3. Howard F.M., Lennon V.A., Finley J., Matsumoto J., Elveback L.R. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci 1987, 505:526-538.
4. Lindstrom J.M., Engel A.G., Seybold M.E., Lennon V.A., Lambert E.H. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J Exp Med 1976, 144:739-753.
5. Richman D.P., Gomez C.M., Berman P.W., Burres S.A., Fitch F.W., Arnason B.G. Monoclonal anti-acetylcholine receptor antibodies can cause experimental myasthenia. Nature 1980, 286:738-739.
6. Shigemoto K., Kubo S., Maruyama N., Hato N., Yamada H., Jie C., et al. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest 2006, 116:1016-1024.
7. Mori S., Shigemoto K. Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis. Autoimmun Rev 2013, 12:912-917. (this issue).
8. Wolf S.D., Dittel B.N., Hardardottir F., Janeway C.A. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 1996, 184:2271-2278.
9. Epstein M.M., Di Rosa F., Jankovic D., Sher A., Matzinger P. Successful T cell priming in B cell-deficient mice. J Exp Med 1995, 182:915-922.
10. Hohlfeld R., Toyka K.V., Heininger K., Grosse-Wilde H., Kalies I. Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature 1984, 310:244-246.
11. Berrih-Aknin S., Cohen-Kaminsky S., Lepage V., Neumann D., Bach J.F., Fuchs S. T-cell antigenic sites involved in myasthenia gravis: correlations with antibody titre and disease severity. J Autoimmun 1991, 4:137-153.
12. Hohlfeld R., Kalies I., Ernst M., Ketelsen U.P., Wekerle H. T-lymphocytes in experimental autoimmune myasthenia gravis. Isolation of T-helper cell lines. J Neurol Sci 1982, 57:265-280.
13. Nath A., Kerman R.H., Novak I.S., Wolinsky J.S. Immune studies in human immunodeficiency virus infection with myasthenia gravis: a case report. Neurology 1990, 40:581-583.
14. Wang Z.Y., Karachunski P.I., Howard J.F., Conti-Fine B.M. Myasthenia in SCID mice grafted with myasthenic patient lymphocytes: role of CD4+ and CD8+ cells. Neurology 1999, 52:484-497.
15. Kaul R., Shenoy M., Goluszko E., Christadoss P. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J Immunol 1994, 152:3152-3157.
16. Marx A., Pfister F., Schalke B., Saruhan-Direskeneli G., Melms A., Ströbel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013, 12:875-884. (this issue).
17. Berrih S., Morel E., Gaud C., Raimond F., Le Brigand H., Bach J.F. Anti-AChR antibodies, thymic histology, and T cell subsets in myasthenia gravis. Neurology 1984, 34:66-71.
18. Leprince C., Cohen-Kaminsky S., Berrih-Aknin S., Vernet-Der Garabedian B., Treton D., Galanaud P., et al. Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis. J Immunol 1990, 145:2115-2122.
19. Newsom-Davis J., Willcox N., Calder L. Thymus cells in myasthenia gravis selectively enhance production of anti-acetylcholine-receptor antibody by autologous blood lymphocytes. N Engl J Med 1981, 305:1313-1318.
20. Lisak R.P., Levinson A.I., Zweiman B., Kornstein M.J. Antibodies to acetylcholine receptor and tetanus toxoid: in vitro synthesis by thymic lymphocytes. J Immunol 1986, 137:1221-1225.
21. Safar D., Berrih-Aknin S., Morel E. Invitro antiacetylcholine receptor antibody-synthesis by myasthenia-gravis patient lymphocytes-correlations with thymic histology and thymic epithelial-cell interactions. J Clin Immunol 1987, 7:225-234.
22. Fujii Y., Hashimoto J., Monden Y., Ito T., Nakahara K., Kawashima Y. Specific activation of lymphocytes against acetylcholine receptor in the thymus in myasthenia gravis. J Immunol 1986, 136:887-891.
23. Yoshikawa H., Satoh K., Yasukawa Y., Yamada M. Analysis of immunoglobulin secretion by lymph organs with myasthenia gravis. Acta Neurol Scand 2001, 103:53-58.
24. Schonbeck S., Padberg F., Hohlfeld R., Wekerle H. Transplantation of thymic autoimmune microenvironment to severe combined immunodeficiency mice. A new model of myasthenia gravis. J Clin Invest 1992, 90:245-250.
25. Aissaoui A., Klingel-Schmitt I., Couderc J., Chateau D., Romagne F., Jambou F., et al. Prevention of autoimmune attack by targeting specific T-cell receptors in a severe combined immunodeficiency mouse model of myasthenia gravis [see comments]. Ann Neurol 1999, 46:559-567.
26. Kuks J.B., Oosterhuis H.J., Limburg P.C., The T.H. Anti-acetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations. J Autoimmun 1991, 4:197-211.
27. Lauriola L., Ranelletti F., Maggiano N., Guerriero M., Punzi C., Marsili F., et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005, 64:536-538.
28. Leite M.I., Strobel P., Jones M., Micklem K., Moritz R., Gold R., et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG. Ann Neurol 2005, 57:444-448.
29. Meraouna A., Cizeron-Clairac G., Panse R.L., Bismuth J., Truffault F., Tallaksen C., et al. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood 2006, 108:432-440.
30. Weiss JM, Cufi P, Le Panse R, Berrih-Aknin S. The thymus in autoimmune Myasthenia Gravis - Paradigm for a tertiary lymphoid organ. Rev Neurol in press.
31. Le Panse R., Bismuth J., Cizeron-Clairac G., Weiss J.M., Cufi P., Dartevelle P., et al. Thymic remodeling associated with hyperplasia in myasthenia gravis. Autoimmunity 2010, 43:401-412.
32. Le Panse R., Cizeron-Clairac G., Bismuth J., Berrih-Aknin S. Microarrays reveal distinct gene signatures in the thymus of seropositive and seronegative myasthenia gravis patients and the role of CC chemokine ligand 21 in thymic hyperplasia. J Immunol 2006, 177:7868-7879.
33. Legler D.F., Loetscher M., Roos R.S., Clark-Lewis I., Baggiolini M., Moser B. B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J Exp Med 1998, 187:655-660.
34. Berrih-Aknin S., Ruhlmann N., Bismuth J., Cizeron-Clairac G., Zelman E., Shachar I., et al. CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia. Ann Neurol 2009, 66:521-531.
35. Luther S.A., Lopez T., Bai W., Hanahan D., Cyster J.G. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 2000, 12:471-481.
36. Drayton D.L., Ying X., Lee J., Lesslauer W., Ruddle N.H. Ectopic LT alpha beta directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase. J Exp Med 2003, 197:1153-1163.
37. Weiss J.M., Cufi P., Bismuth J., Eymard B., Fadel E., Berrih-Aknin S., et al. SDF-1/CXCL12 recruits B cells and antigen-presenting cells to the thymus of autoimmune myasthenia gravis patients. Immunobiology 2013, 218:373-381.
38. Youinou P., Renaudineau Y. The paradox of CD5-expressing B cells in systemic lupus erythematosus. Autoimmun Rev 2007, 7:149-154.
39. Yi Q., Ahlberg R., Pirskanen R., Lefvert A. Levels of CD5+ B lymphocytes do not differ between patients with myasthenia gravis and healthy individuals. Neurology 1992, 42:1081-1084.
40. Ragheb S., Lisak R.P. Effect of clinical status and treatment on the frequency of CD5+ B cells in patients with myasthenia gravis. Neurology 1992, 42:1076-1080.
41. Araga S., Kishimoto M., Adachi A., Nakayasu H., Takenaka T., Takahashi K. The CD5+ B cells and myasthenia gravis. Autoimmunity 1995, 20:129-134.
42. Heidenreich F., Jovin T. Synthesis of anti-acetylcholine receptor antibodies by CD5- B cells from peripheral blood of myasthenia gravis patients. J Neurol 1996, 243:57-62.
43. Ragheb S., Bealmear B., Lisak R. Cell-surface expression of lymphocyte activation markers in myasthenia gravis. Autoimmunity 1999, 31:55-66.
44. Murai H., Hara H., Hatae T., Kobayashi T., Watanabe T. Expression of CD23 in the germinal center of thymus from myasthenia gravis patients. J Neuroimmunol 1997, 76:61-69.
45. Levinson A.I., Zweiman B., Lisak R.P., Dziarski A., Moskovitz A.R. Thymic B-cell activation in myasthenia gravis. Neurology 1984, 34:462-468.
46. Auner H.W., Beham-Schmid C., Dillon N., Sabbattini P. The life span of short-lived plasma cells is partly determined by a block on activation of apoptotic caspases acting in combination with endoplasmic reticulum stress. Blood 2010, 116:3445-3455.
47. Arce S., Cassese G., Hauser A., Dorner T., Odendahl M., Manz R., et al. The role of long-lived plasma cells in autoimmunity. Immunobiology 2002, 206:558-562.
48. Yoshikawa H., Lennon V. ACh receptor protein drives primary and memory autoantibody responses in chimeric human-SCID mice. Clin Immunol 2002, 104:128-137.
49. Cavalcante P., Serafini B., Rosicarelli B., Maggi L., Barberis M., Antozzi C., et al. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol 2010, 67:726-738.
50. Kakalacheva K., Maurer M.A., Tackenberg B., Munz C., Willcox N., Lunemann J.D. Intrathymic Epstein-Barr virus infection is not a prominent feature of myasthenia gravis. Ann Neurol 2011, 70:508-514.
51. Meyer M., Hols A.K., Liersch B., Leistner R., Gellert K., Schalke B., et al. Lack of evidence for Epstein-Barr virus infection in myasthenia gravis thymus. Ann Neurol 2011, 70:515-518.
52. Csuka D., Banati M., Rozsa C., Füst G., Illes Z. High anti-EBNA-1 IgG levels are associated with early-onset myasthenia gravis. Eur J Neurol 2012, 19:842-846.
53. Cavalcante P., Cufi P., Mantegazza R., Berrih-Aknin S., Bernasconi P., Le Panse R. Etiology of myasthenia gravis: Innate immunity signature in pathological thymus. Autoimmun Rev 2013, 12:863-874. (this issue).
54. Famularo G., Giacomelli R., Alesse E., Cifone M.G., Morrone S., Boirivant M., et al. Polyclonal B lymphocyte activation in progressive systemic sclerosis. J Clin Lab Immunol 1989, 29:59-63.
55. Levinson A.I., Dziarski A., Lisak R.P., Zweiman B., Moskovitz A.R., Brenner T., et al. Polyclonal B-cell activity in myasthenia gravis. Neurology 1981, 31:1198-1201.
56. Limburg P., Hummel-Tappel E., Oosterhuis H., The T. In vitro T-cell dependent B-cell activity in myasthenia gravis. Clin Exp Immunol 1985, 61:31-38.
57. Yoshikawa H., Satoh K., Yasukawa Y., Yamada M. Cytokine secretion by peripheral blood mononuclear cells in myasthenia gravis. J Clin Neurosci 2002, 9:133-136.
58. Romi F., Skeie G.O., Aarli J.A., Gilhus N.E. Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol 2000, 247:369-375.
59. Simpson J.A. Immunological disturbances in myasthenia gravis with a report of Hashimoto's disease developing after thymectomy. J Neurol Neurosurg Psychiatry 1964, 27:485-492.
60. Thorlacius S., Aarli J.A., Riise T., Matre R., Johnsen H.J. Associated disorders in myasthenia gravis: autoimmune diseases and their relation to thymectomy. Acta Neurol Scand 1989, 80:290-295.
61. Guigou V., Emilie D., Berrih-Aknin S., Fumoux F., Fougereau M., Schiff C. Individual germinal centres of myasthenia gravis human thymuses contain polyclonal activated B cells that express all the Vh and Vk families. Clin Exp Immunol 1991, 83:262-266.
62. Sims G., Shiono H., Willcox N., Stott D. Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J Immunol 2001, 167:1935-1944.
63. Zuckerman N.S., Howard W.A., Bismuth J., Gibson K., Edelman H., Berrih-Aknin S., et al. Ectopic GC in the thymus of myasthenia gravis patients show characteristics of normal GC. Eur J Immunol 2010, 40:1150-1161.
64. Cohen-Kaminsky S., Devergne O., Delattre R.M., Klingel-Schmitt I., Emilie D., Galanaud P., et al. Interleukin-6 overproduction by cultured thymic epithelial cells from patients with myasthenia gravis is potentially involved in thymic hyperplasia. Eur Cytokine Netw 1993, 4:121-132.
65. Aricha R., Mizrachi K., Fuchs S., Souroujon M.C. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun 2011, 36:135-141.
66. Tanaka T., Kishimoto T. Immunotherapeutic implication of IL-6 blockade. Immunotherapy 2012, 4:87-105.
67. Reina-San-Martin B., Cosson A., Minoprio P. Lymphocyte polyclonal activation: a pitfall for vaccine design against infectious agents. Parasitol Today 2000, 16:62-67.
68. Montes C., Acosta-Rodríguez E., Merino M., Bermejo D., Gruppi A. Polyclonal B cell activation in infections: infectious agents' devilry or defense mechanism of the host?. J Leukoc Biol 2007, 82:1027-1032.
69. Kiefer K., Oropallo M.A., Cancro M.P., Marshak-Rothstein A. Role of type I interferons in the activation of autoreactive B cells. Immunol Cell Biol 2012, 90:498-504.
70. Cufi P., Dragin N., Weiss J.M., Martinez-Martinez P., De Baets M., Roussin R., et al. Implication of dsRNA signaling in the etiology of autoimmune myasthenia gravis. Ann Neurol 2013, 73:281-293.
71. Moore P.A., Belvedere O., Orr A., Pieri K., LaFleur D.W., Feng P., et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285:260-263.
72. Schneider P., MacKay F., Steiner V., Hofmann K., Bodmer J.L., Holler N., et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189:1747-1756.
73. Karpusas M., Cachero T.G., Qian F., Boriack-Sjodin A., Mullen C., Strauch K., et al. Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes. J Mol Biol 2002, 315:1145-1154.
74. Liu Y., Xu L., Opalka N., Kappler J., Shu H.B., Zhang G. Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell 2002, 108:383-394.
75. Oren D.A., Li Y., Volovik Y., Morris T.S., Dharia C., Das K., et al. Structural basis of BLyS receptor recognition. Nat Struct Biol 2002, 9:288-292.
76. Kalled S.L., Ambrose C., Hsu Y.M. The biochemistry and biology of BAFF, APRIL and their receptors. Curr Dir Autoimmun 2005, 8:206-242.
77. Sasaki Y., Casola S., Kutok J.L., Rajewsky K., Schmidt-Supprian M. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol 2004, 173:2245-2252.
78. Shulga-Morskaya S., Dobles M., Walsh M.E., Ng L.G., MacKay F., Rao S.P., et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 2004, 173:2331-2341.
79. Bossen C., Schneider P. BAFF, APRIL and their receptors: Structure, function and signaling. Semin Immunol 2006, 18:263-275.
80. Ng L.G., Sutherland A.P.R., Newton R., Qian F., Cachero T.G., Scott M.L., et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004, 173:807-817.
81. Yan M., Wang H., Chan B., Roose-Girma M., Erickson S., Baker T., et al. Activation and accumulation of B cells in TACI-deficient mice. Nat Immunol 2001, 2:638-643.
82. Seshasayee D., Valdez P., Yan M., Dixit V.M., Tumas D., Grewal I.S. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003, 18:279-288.
83. Sakurai D., Kanno Y., Hase H., Kojima H., Okumura K., Kobata T. TACI attenuates antibody production costimulated by BAFF-R and CD40. Eur J Immunol 2007, 37:110-118.
84. Salzer U., Chapel H.M., Webster A.D., Pan-Hammarstrom Q., Schmitt-Graeff A., Schlesier M., et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 2005, 37:820-828.
85. Schiemann B., Gommerman J.L., Vora K., Cachero T.G., Shulga-Morskaya S., Dobles M., et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001, 293:2111-2114.
86. Xu S.L., Lam K.P. B-cell maturation protein, which binds the tumor necrosis factor family members BAFF and APRIL, is dispensable for humoral immune responses. Mol Cell Biol 2001, 21:4067-4074.
87. Avery D.T., Kalled S.L., Ellyard J.I., Ambrose C., Bixler S.A., Thien M., et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003, 112:286-297.
88. Zhang X., Park C.S., Yoon S.O., Li L., Hsu Y.M., Ambrose C., et al. BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors. Int Immunol 2005, 17:779-788.
89. Darce J.R., Arendt B.K., Wu X.S., Jelinek D.F. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007, 179:7276-7286.
90. MacLennan I.C.M., Vinuesa C.G. Dendritic cells, BAFF, and APRIL: Innate players in adaptive antibody responses. Immunity 2002, 17:235-238.
91. Rolink A.G., Tschopp J., Schneider P., Melchers F. BAFF is a survival and maturation factor for mouse B cells. Eur J Immunol 2002, 32:2004-2010.
92. Mackay F., Schneider P. Cracking the BAFF code. Nat Rev Immunol 2009, 9:491-502.
93. Mackay F., Woodcock S.A., Lawton P., Ambrose C., Baetscher M., Schneider P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
94. Khare S.D., Sarosi I., Xia X.Z., McCabe S., Miner K., Solovyev I., et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci U S A 2000, 97:3370-3375.
95. Rodig S.J., Shahsafaei A., Li B., Mackay C.R., Dorfman D.M. BAFF-R, the major B cell-activating factor receptor, is expressed on most mature B cells and B-cell lymphoproliferative disorders. Hum Pathol 2005, 36:1113-1119.
96. Sun M., Fink P.J. A new class of reverse signaling costimulators belongs to the TNF family. J Immunol 2007, 179:4307-4312.
97. Bossen C., Tardivel A., Willen L., Fletcher C.A., Perroud M., Beermann F., et al. Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses. Eur J Immunol 2011, 41:787-797.
98. Lesley R., Xu Y., Kalled S.L., Hess D.M., Schwab S.R., Shu H.B., et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004, 20:441-453.
99. Thien M., Phan T.G., Gardam S., Amesbury M., Basten A., Mackay F., et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
100. Ota M., Duong B.H., Torkamani A., Doyle C.M., Gavin A.L., Ota T., et al. Regulation of the B Cell Receptor Repertoire and Self-Reactivity by BAFF. J Immunol 2010, 185:4128-4136.
101. Brink R. Regulation of B cell self-tolerance by BAFF. Semin Immunol 2006, 18:276-283.
102. Kalled S.L. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol 2006, 18:290-296.
103. Nardelli B., Belvedere O., Roschke V., Moore P.A., Olsen H.S., Migone T.S., et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001, 97:198-204.
104. Craxton A., Magaletti D., Ryan E.J., Clark E.A. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood 2003, 101:4464-4471.
105. Gandhi K.S., Mckay F.C., Schibeci S.D., Arthur J.W., Heard R.N., Stewart G.J., et al. BAFF is a biological response marker to IFN-beta treatment in multiple sclerosis. J Interferon Cytokine Res 2008, 28:529-539.
106. Krumbholz M., Faber H., Steinmeyer F., Hoffmann L.A., Kumpfel T., Pellkofer H., et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008, 131:1455-1463.
107. Hanada T., Yoshida H., Kato S., Tanaka K., Masutani K., Tsukada J., et al. Suppressor of cytokine signaling-1 is essential for suppressing dendritic cell activation and systemic autoimmunity. Immunity 2003, 19:437-450.
108. Kim J.Y., Yang Y., Moon J.S., Lee E.Y., So S.H., Lee H.S., et al. Serum BAFF expression in patients with myasthenia gravis. J Neuroimmunol 2008, 199:151-154.
109. Ragheb S., Lisak R., Lewis R., Van Stavern G., Gonzales F., Simon K. A potential role for B-cell activating factor in the pathogenesis of autoimmune myasthenia gravis. Arch Neurol 2008, 65:1358-1362.
110. Scuderi F., Alboini P.E., Bartoccioni E., Evoli A. BAFF serum levels in myasthenia gravis: effects of therapy. J Neurol 2011, 258:2284-2285.
111. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976, 26:1054-1059.
112. Roses A.D., Olanow C.W., Mcadams M.W., Lane R.J.M. No direct correlation between serum anti-acetylcholine receptor antibody-levels and clinical state of individual patients with myasthenia-gravis. Neurology 1981, 31:220-224.
113. Li X., Xiao B.G., Xi J.Y., Lu C.Z., Lu J.H. Decrease of CD4(+)CD25(high)Foxp3(+) regulatory T cells and elevation of CD19(+)BAFF-R(+) B cells and soluble ICAM-1 in myasthenia gravis. Clin Immunol 2008, 126:180-188.
114. Thangarajh M., Kisiswa L., Pirskanen R., Hillert J. The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthenia gravis. Scand J Immunol 2007, 65:461-466.
115. Ragheb S., Lisak R.P. The thymus and myasthenia gravis. Chest Surg Clin N Am 2001, 11:311-327. [x].
116. Hohlfeld R., Wekerle H. Reflections on the "intrathymic pathogenesis" of myasthenia gravis. J Neuroimmunol 2008, 201:21-27.
117. Onodera J., Nakamura S., Nagano I., Tobita M., Yoshioka M., Takeda A., et al. Upregulation of Bcl-2 protein in the myasthenic thymus. Ann Neurol 1996, 39:521-528.
118. Shiono H., Fujii Y., Okumura M., Takeuchi Y., Inoue M., Matsuda H. Failure to down-regulate Bcl-2 protein in thymic germinal center B cells in myasthenia gravis. Eur J Immunol 1997, 27:805-809.
119. Thangarajh M., Masterman T., Helgeland L., Rot U., Jonsson M., Eide G., et al. The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis. J Neuroimmunol 2006, 178:161-166.
120. Aloisi F., Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006, 6:205-217.
121. Badr G., Borhis G., Lefevre E.A., Chaoul N., Deshayes F., Dessirier V., et al. BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells. Blood 2008, 111:2744-2754.
122. Shiao Y.M., Lee C.C., Hsu Y.H., Huang S.F., Lin C.Y., Li L.H., et al. Ectopic and high CXCL13 chemokine expression in myasthenia gravis with thymic lymphoid hyperplasia. J Neuroimmunol 2010, 221:101-106.
123. Heino M., Peterson P., Kudoh J., Nagamine K., Lagerstedt A., Ovod V., et al. Autoimmune regulator is expressed in the cells regulating immune tolerance in thymus medulla. Biochem Biophys Res Commun 1999, 257:821-825.
124. Kogawa K., Nagafuchi S., Katsuta H., Kudoh J., Tamiya S., Sakai Y., et al. Expression of AIRE gene in peripheral monocyte/dendritic cell lineage. Immunol Lett 2002, 80:195-198.
125. Rizzi M., Ferrera F., Filaci G., Indiveri F. Disruption of immunological tolerance: role of AIRE gene in autoimmunity. Autoimmun Rev 2006, 5:145-147.
126. Ramsey C., Hassler S., Marits P., Kampe O., Surh C.A., Peltonen L., et al. Increased antigen presenting cell-mediated T cell activation in mice and patients without the autoimmune regulator. Eur J Immunol 2006, 36:305-317.
127. Hassler S., Ramse C., Karlsson M.C., Larsson D., Herrmann B., Rozell B., et al. Aire-deficient mice develop hematopoetic irregularities and marginal zone B-cell lymphoma. Blood 2006, 108:1941-1948.
128. Lindh E., Lind S.M., Lindmark E., Hassler S., Perheentupa J., Peltonen L., et al. AIRE regulates T-cell-independent B-cell responses through BAFF. Proc Natl Acad Sci U S A 2008, 105:18466-18471.
129. Aricha R., Feferman T., Scott H.S., Souroujon M.C., Berrih-Aknin S., Fuchs S. The susceptibility of Aire(-/-) mice to experimental myasthenia gravis involves alterations in regulatory T cells. J Autoimmun 2011, 36:16-24.
130. Ragheb S., Lisak R. The immunopathogenesis of acquired (autoimmune) myasthenia gravis. Handbook of myasthenia gravis and myasthenic syndromes 1994, 239-276. Marcel Dekker, New York. R. Lisak (Ed.).
131. Ragheb S., Lisak R.P. Immune regulation and myasthenia gravis. Ann N Y Acad Sci 1998, 841:210-224.
132. Weiner G.J. Rituximab: mechanism of action. Semin Hematol 2010, 47:115-123.
133. Diaz-Lagares C., Croca S., Sangle S., Vital E.M., Catapano F., Martinez-Berriotxoa A., et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012, 11:357-364.
134. Narvaez J., Rios-Rodriguez V., de la Fuente D., Estrada P., Lopez-Vives L., Gomez-Vaquero C., et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum 2011, 41:364-372.
135. Ye Y., Qian J., Gu Y., Chen X., Ye S. Rituximab in the treatment of severe lupus myelopathy. Clin Rheumatol 2011, 30:981-986.
136. Ramos-Casals M., Diaz-Lagares C., Soto-Cardenas M.J., Brito-Zeron P., Cuadrado M.J., Sanna G., et al. Rituximab therapy in lupus nephritis: current clinical evidence. Clin Rev Allergy Immunol 2011, 40:159-169.
137. Vital E.M., Dass S., Buch M.H., Henshaw K., Pease C.T., Martin M.F., et al. B cell biomarkers of rituximab responses in systemic lupus erythematosus. Arthritis Rheum 2011, 63:3038-3047.
138. Haraoui B., Bokarewa M., Kallmeyer I., Bykerk V.P. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial. J Rheumatol 2011, 38:2548-2556.
139. Boumans M.J., Vos K., Gerlag D.M., Tak P.P. Biological treatment of rheumatoid arthritis: towards a more cost-effective re-treatment regimen using rituximab?. Ann Rheum Dis 2012, 71:472-473.
140. Solau-Gervais E., Prudhomme C., Philippe P., Duhamel A., Dupont-Creteur C., Legrand J.L., et al. Efficacy of rituximab in the treatment of rheumatoid arthritis. Influence of serologic status, coprescription of methotrexate and prior TNF-alpha inhibitors exposure. Joint Bone Spine 2012, 79:281-284.
141. Yazici Y. Rheumatoid arthritis: When should we use rituximab to treat RA?. Nat Rev Rheumatol 2011, 7:379-380.
142. Meijer J.M., Meiners P.M., Vissink A., Spijkervet F.K., Abdulahad W., Kamminga N., et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010, 62:960-968.
143. Mekinian A., Ravaud P., Hatron P.Y., Larroche C., Leone J., Gombert B., et al. Efficacy of rituximab in primary Sjogren's syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis 2012, 71:84-87.
144. Meiners P.M., Vissink A., Kallenberg C.G., Kroese F.G., Bootsma H. Treatment of primary Sjogren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?. Expert Opin Biol Ther 2011, 11:1381-1394.
145. Vossenkamper A., Lutalo P.M., Spencer J. Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjogren's syndrome: clinical implications and effects of B cell-targeted therapies. Clin Exp Immunol 2012, 167:7-14.
146. Pranzatelli M.R., Tate E.D., Travelstead A.L., Barbosa J., Bergamini R.A., Civitello L., et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006, 28:585-593.
147. Capobianco M., Malucchi S., di Sapio A., Gilli F., Sala A., Bottero R., et al. Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci 2007, 28:209-211.
148. Cree B.A., Lamb S., Morgan K., Chen A., Waubant E., Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005, 64:1270-1272.
149. Jacob A., Weinshenker B.G., Violich I., McLinskey N., Krupp L., Fox R.J., et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008, 65:1443-1448.
150. Gajra A., Vajpayee N., Grethlein S.J. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma. Am J Hematol 2004, 77:196-197.
151. Hain B., Jordan K., Deschauer M., Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006, 33:575-580.
152. Lindberg C., Bokarewa M. Rituximab for severe myasthenia gravis-experience from five patients. Acta Neurol Scand 2010, 122:225-228.
153. Maddison P., McConville J., Farrugia M.E., Davies N., Rose M., Norwood F., et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011, 82:671-673.
154. Nowak R.J., Dicapua D.B., Zebardast N., Goldstein J.M. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 2011, 4:259-266.
155. Stein B., Bird S.J. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis. J Clin Neuromuscul Dis 2011, 12:163-164.
156. Stieglbauer K., Topakian R., Schaffer V., Aichner F.T. Rituximab for myasthenia gravis: three case reports and review of the literature. J Neurol Sci 2009, 280:120-122.
157. Thakre M., Inshasi J., Marashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol 2007, 254:968-969.
158. Wylam M.E., Anderson P.M., Kuntz N.L., Rodriguez V. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr 2003, 143:674-677.
159. Zebardast N., Patwa H.S., Novella S.P., Goldstein J.M. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve 2010, 41:375-378.
160. Evoli A., Padua L. Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev 2013, 12:931-935. (this issue).
161. Leite M.I., Jacob S., Viegas S., Cossins J., Clover L., Morgan B.P., et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008, 131:1940-1952.
162. Lavie F., Miceli-Richard C., Ittah M., Sellam J., Gottenberg J.E., Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007, 66:700-703.
163. Pers J.O., Devauchelle V., Daridon C., Bendaoud B., Le Berre R., Bordron A., et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjogren's syndrome. Arthritis Rheum 2007, 56:1464-1477.
164. Pranzatelli M.R., Tate E.D., Travelstead A.L., Verhulst S.J. Chemokine/cytokine profiling after rituximab: reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS. Cytokine 2011, 53:384-389.
165. Vallerskog T., Heimburger M., Gunnarsson I., Zhou W., Wahren-Herlenius M., Trollmo C., et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006, 8:R167.
166. Awan F.T., Lapalombella R., Trotta R., Butchar J.P., Yu B., Benson D.M., et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2010, 115:1204-1213.
167. Horton H.M., Bernett M.J., Pong E., Peipp M., Karki S., Chu S.Y., et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008, 68:8049-8057.
168. Hammer O. CD19 as an attractive target for antibody-based therapy. MAbs 2012, 4:571-577.
169. Richardson P.G., Mitsiades C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Future Oncol 2005, 1:161-171.
170. Neubert K., Meister S., Moser K., Weisel F., Maseda D., Amann K., et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008, 14:748-755.
171. Frohlich K., Holle J.U., Aries P.M., Gross W.L., Moosig F. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma. Ann Rheum Dis 2011, 70:1344-1345.
172. Gomez A.M., Vrolix K., Martinez-Martinez P., Molenaar P.C., Phernambucq M., van der Esch E., et al. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol 2011, 186:2503-2513.
173. Baker K.P., Edwards B.M., Main S.H., Choi G.H., Wager R.E., Halpern W.G., et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003, 48:3253-3265.
174. Navarra S.V., Guzman R.M., Gallacher A.E., Hall S., Levy R.A., Jimenez R.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731.
175. Lin W.Y., Gong Q., Seshasayee D., Lin Z., Ou Q., Ye S., et al. Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade. Blood 2007, 110:3959-3967.
176. Carbonatto M., Yu P., Bertolino M., Vigna E., Steidler S., Fava L., et al. Nonclinical safety, pharmacokinetics, and pharmacodynamics of atacicept. Toxicol Sci 2008, 105:200-210.
177. Dall'Era M., Chakravarty E., Wallace D., Genovese M., Weisman M., Kavanaugh A., et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007, 56:4142-4150.
178. Tak P.P., Thurlings R.M., Rossier C., Nestorov I., Dimic A., Mircetic V., et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008, 58:61-72.
179. Hartung H.-P., Kieseier B. Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord 2010, 3:205-216.
180. von Bulow G.U., van Deursen J.M., Bram R.J. Regulation of the T-independent humoral response by TACI. Immunity 2001, 14:573-582.
181. Ragheb S., Li Y., Simon K., VanHaerents S., Galimberti D., De Riz M., et al. Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler 2011, 17:819-829.
182. Johns T.R. Treatment of myasthenia gravis: long-term administration of corticosteroids with remarks on thymectomy. Adv Neurol 1977, 17:99-122.
183. Mann J.D., Johns T.R., Campa J.F. Long-term administration of corticosteroids in myasthenia gravis. Neurology 1976, 26:729-740.
184. Acsadi A., Lisak R. Myasthenia gravis. Curr Treat Options Neurol 2010, 12:221-243.
185. Jani-Acsadi A., Lisak R.P. Myasthenic crisis: Guidelines for prevention and treatment. J Neurol Sci 2007, 261:127-133.
186. Barth D., Nabavi Nouri M., Ng E., Nwe P., Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011, 76:2017-2023.
187. Meriggioli M.N. IVIG in myasthenia gravis: getting enough "bang for the buck". Neurology 2007, 68:803-804.
188. Zinman L., Bril V. IVIG treatment for myasthenia gravis: effectiveness, limitations, and novel therapeutic strategies. Ann N Y Acad Sci 2008, 1132:264-270.
189. Zen M., Canova M., Campana C., Bettio S., Nalotto L., Rampudda M., et al. The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 2011, 10:305-310.
190. Le Pottier L., Bendaoud B., Dueymes M., Daridon C., Youinou P., Shoenfeld Y., et al. BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer. J Clin Immunol 2007, 27:257-265.